Ether compounds

Details Ether compounds Ether compounds

2007-03-20

2007-03-20

Keys, Rosalynd (Department: 1621)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Phosphorus containing other than solely as part of an...

C514S075000, C514S137000, C514S144000, C514S183000, C514S360000, C514S451000, C514S461000, C514S506000, C514S553000, C514S557000, C514S600000, C514S602000, C514S722000, C514S723000

Reexamination Certificate

active

10893791

ABSTRACT:
The present invention relates to novel ether compounds, compositions comprising ether compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

REFERENCES:
patent: 3152148 (1964-10-01), Easterly et al.
patent: 3773946 (1973-11-01), Creger
patent: 3930024 (1975-12-01), Creger
patent: 4287200 (1981-09-01), Kawamatsu et al.
patent: 4584321 (1986-04-01), Manghisi et al.
patent: 4613593 (1986-09-01), Yamatsu et al.
patent: 4634719 (1987-01-01), Takaishi et al.
patent: 4689344 (1987-08-01), Bar-Tana
patent: 4711896 (1987-12-01), Bar-Tana et al.
patent: 4714762 (1987-12-01), Hoefle et al.
patent: 5166174 (1992-11-01), Ueno et al.
patent: 5225439 (1993-07-01), Ueno et al.
patent: 5284858 (1994-02-01), Ueno et al.
patent: 5380709 (1995-01-01), Ueno et al.
patent: 5428062 (1995-06-01), Ueno et al.
patent: 5648387 (1997-07-01), Bisgaier et al.
patent: 5750569 (1998-05-01), Bisgaier et al.
patent: 5756344 (1998-05-01), Onda et al.
patent: 5756544 (1998-05-01), Bisgaier et al.
patent: 5783600 (1998-07-01), Bisgaier et al.
patent: 5834596 (1998-11-01), Ageland et al.
patent: 5886034 (1999-03-01), Ueno et al.
patent: 6004925 (1999-12-01), Dasseux et al.
patent: 6037323 (2000-03-01), Dasseux
patent: 6459003 (2002-10-01), Dasseux et al.
patent: 6703422 (2004-03-01), Dasseux et al.
patent: 6790953 (2004-09-01), Dasseux et al.
patent: 2005/0119333 (2005-06-01), Dasseux et al.
patent: 88300709.8 (1988-01-01), None
patent: 2013926 (1970-04-01), None
patent: 1269658 (1972-03-01), None
patent: WO 96/30328 (1996-10-01), None
patent: WO096/30328 (1996-10-01), None
patent: WO 98/30530 (1998-07-01), None
patent: WO 99/00116 (1999-01-01), None
Richard B. Silverman, The Organic Chemistry of Drug Design and Drug Action, 1992, pp. 15-22.
Ackerly, et al., 1995, “A novel approach to dual-acting thromboxane receptor antagonist/synthase inhibitors based on the link of 1,3-dioxane-thrombaxane receptor antagonists and -thromboxane synthase inhibitors,” J. Med. Chem. 38:1608-1628.
Acton et al., 1996, “Identification of scavenger receptor SR-BI as a high density lipoprotein receptor,” Science. 271(5248):518-20.
Ahrens et al., 1967, “A direct method for preparing pyridoxal and 4-pyridoxic acid (1),” J. Heterocycl. Chem. 4:625-26.
Alexander, K et al., 1948, “4,4′-Dichlorodibutyl ether and its derivatives from tetrahydrofuran,” J. Am. Chem. Soc. 70:1839-42.
Badimon et al., 1992, “Role of high density lipoproteins in the regression of atherosclerosis,” Circulation 86(6 Suppl):III86-94.
Bailey, et al., 1990, “Convenient general method for the preparation ofprimary alkeyllithiums by lithium-iodine exchange,” J. Org. Chem. 55:5404-06.
Barrans et al., 1996, “Pre-beta HDL; structure and metabolism,” Biochim. Biophys. Acta. 1300(2):73-85.
Becker et al., 1982, “Intramolecular photoaddition of terminal allenes to conjugated cyclohexenones,” J. Org. Chem. 47:3297-3310.
Bernady et al., 1979, “Prostaglandins and congeners. 20.1.2Synthesis of prostaglandins via conjugate addition of lithiummmtrans-1-alkenyltrialkylalanate reagents. A novel reagent for conjugate 1,4-additions,” J. Org. Chem. 44:1438-47.
Bhanot et al., 1977, “Synthetic Studies on Terpenoids.5.Syntheses of γ- and δ-Lactones from β-(2,7-Dimethyl-1,2-dihydroxycycloheptyl)propionic Acid,” J. Org. Chem. 42:1623-1627.
Bisgaier et al., 1998, “A novel compound that elevates high density lipoprotein and activates the peroxisome proliferator activated receptor,” J Lipid Res. 39(1):17-30.
Bisgaier et al., 1997, “Attenuation of plasma low density lipoprotein cholesterol by select 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in mice devoid of low density lipoprotein receptors,” J Lipid Res 38(12):2502-2515.
Böhrne, H. et al., 1955, Am. Chem., 595: 169-178 (English language abstract).
Bongini et al., 1979, “A simple and practical method for tetrahydropyranylation of alcohols and phenols,” Synthesis 618-620.
Brown et al., 1965, “Selective reductions. VII. Reaction of lithium trimethoxyluminohydride with selected organic compounds containing representative functional groups,” J. Am. Chem . Soc. 87:5614-20.
Brown et al., 1980, “Selective reductions. 26 Lithium triethylborohydride as an exceptionally powerful and selective reducing agent in organic synthesis. Exploration of the reactions with selected organic compounds containing representative functional groups,1,2,” J. Org. Chem 45:1-12.
Bruce et al., 1998, “Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport,” Annu Rev Nutr. 1998;18:297-330.
Campagna et al., 1994, “Cyclic Amidine Analogues of Taurine and Homotaurine: Synthesis and Effects on Rat Skeletal Muscle,” Farmaco, Ed. Sci 49:653-658.
Carothers, 1924, “Platinum oxide as a catalyst in the reduction of organic compounds. V. The preparation of primary alcohols by the catalytic hydrogenation of aldehydes1,” J. Am. Chem. Soc. 46:1675-83.
Cerny et al., 1969, “Properties of Sodium Bis-(2-Methoxyethoxy—Aluminum Hydride,” Collect Czech Chem Commn. 34:1025-33.
Chadwick et al., 1979, “Reaction between N-Alkylpyrroles and Alkyl-lithium Reagents”J. Chem Soc., Perkin Trans. I 2845.
Chaikin et al., 1949, “Lithium Borohydride as a Reducing Agent,” J. Am. Chem. Soc. 71:3245-46.
Chen et al., 1998, “Asymetric total synthesis of phosphatidylinositol 3-phosphate and 4-phosphate derivatives,” J. Org. Chem. 63:6511-22.
Comins et al., 1981, “A one pot synthesis of unsymmetrical secondary alcohols from two grignard reagents,” Tetrahedron Lett. 22:1085-88.
Corbridge, 1985, “Phosphorus: An Outline of Its Chemistry, Biochemistry and Technology,” Studies in Inorganic Chemistry, 3RDed, pp. 357-395.
Corey et al., 1978, “Total Synthesis of (S)-12—Hydroxy-5,8,14-cis,-10-trans-cicosatetraenoic Acid (Samuelsson's HETE),” J. Am. Chem Soc. 100:1942-1943.
Corey et al., 1979, “A useful procedures for the oxidation of alcohols involving pyridinum dichromate in aprotic media,” Tetrahedron Lett. 5: 399-402.
Corey et al., 1967, “useful method for the conversion of alcohols into iodides,” J. Org. Chem. 32: 4160-4161.
Danheiser et al., 1991, “A Practical and Efficient Method for Synthesis of β-Lactones,” J. Org. Chem. 56:1176-85.
Dansky HM, Fisher EA, 1999, “High-density lipoprotein and plaque regression: the good cholesterol gets even better,” Circulation 100(17):1762-3.
Decossin et al., 1997, “Subclasses of LpA-1 in coronary artery disease: distribution and cholesterol efflux ability,” Eur J Clin Invest. 27(4):299-307.
DeSarlo et al., 1971, “Isoxazolin-5-one,” J. Chem Soc.86-89.
Eaton et al., 1972, “Hydroxypropylation,” J. Org. Chem. 37:1947-50.
Ehlinger, et al., 1980, “Silicon in Synthesis. 10. The (trimethylsilyl)allyl Anion: A β-Acyl anion equivalent for the conversion of aldehydes and ketones into λ-lactones,” J. Am. Chem. Soc. 102:5004-11.
Eisch et al., 1978, “Synthesis of lactones via the titanium-catalyzed hydromagnesiation of alkenols,” J. Organo. Met. Chem. 160:C8-

Affiliated with

Also associated with

Rating

Ether compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Ether compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ether compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3778076